Natural Killer Cell Immunotherapy for Osteosarcoma

Biology of Natural Killer Cells

Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902 · see citing works

In search of the ‘missing self’: MHC molecules and NK cell recognition

Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687 · see citing works

Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis

Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,773 · see citing works

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · see citing works

Human Diversity in Killer Cell Inhibitory Receptor Genes

Uhrberg, M., Valiante, N. M., Shum, B. P., Shilling, H. G., Lienert-Weidenbach, K., Corliss, B. C., Tyan, D. B., Lanier, L. L., & Parham, P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80394-5 · Cited by 1,060 · see citing works

New aspects of natural-killer-cell surveillance and therapy of cancer

Smyth, M. J., Hayakawa, Y., Takeda, K., & Yagita∥, H. (2002) · Nature reviews. Cancer · doi:10.1038/nrc928 · Cited by 750 · see citing works

Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells

Denman, C. J., Senyukov, V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L. V., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683 · see citing works

NK cells and cancer immunosurveillance

Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682 · see citing works

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

Imai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 661 · see citing works

Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T. D., Eldridge, P. W., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 597 · see citing works

Natural Killer (NK) Cell–mediated Cytotoxicity: Differential Use of TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells

Zamai, L., Ahmad, M., Bennett, I. M., Azzoni, L., Alnemri, E. S., & PERUSSIA, B. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2375 · Cited by 564 · see citing works

Activating and inhibitory receptors of natural killer cells

Pegram, H. J., Andrews, D. M., Smyth, M. J., Darcy, P. K., & Kershaw, M. H. (2010) · Immunology and Cell Biology · doi:10.1038/icb.2010.78 · Cited by 557 · see citing works

Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis

Smyth, M. J., Cretney, E., Takeda, K., Wiltrout, R. H., Sedger, L. M., Kayagaki, N., Yagita∥, H., & Okumura, K. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.661 · Cited by 512 · see citing works

Human natural killer cell development and biology

Farag, S. S., & Caligiuri, M. A. (2005) · Blood Reviews · doi:10.1016/j.blre.2005.10.001 · Cited by 504 · see citing works

Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression

Parkhurst, M. R., Riley, J. P., Dudley, M. E., & Rosenberg, S. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1347 · Cited by 477 · see citing works

Treatment of patients with advanced cancer with the natural killer cell line NK-92

Tonn, T., Schwabe, D., Klingemann, H., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 465 · see citing works

Oncogenic stress sensed by the immune system: role of natural killer cell receptors

Raulet, D. H., & Guerra, N. (2009) · Nature reviews. Immunology · doi:10.1038/nri2604 · Cited by 396 · see citing works

Expression and Function of TNF-Related Apoptosis-Inducing Ligand on Murine Activated NK Cells

Kayagaki, N., Yamaguchi, N., Nakayama, M., Takeda, K., Akiba, H., Tsutsui, H., Okamura, H., Nakanishi, K., Okumura, K., & Yagita∥, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.1906 · Cited by 338 · see citing works

A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells

Chang, Y.-H., Connolly, J. G., Shimasaki, N., Mimura, K., Kono, K., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3558 · Cited by 329 · see citing works

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application

Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N. S., Kumar, S. K., Chauhan, D., Treon, S. P., Richardson, P. G. G., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05286.x · Cited by 323 · see citing works

Hypoxia downregulates the expression of activating receptors involved in NK ‐cell‐mediated target cell killing without affecting ADCC

Balsamo, M., Manzini, C., Pietra, G., Raggi, F., Blengio, F., Mingari, M. C., Varesio, L., Moretta, L., Bosco, M. C., & Vitale, M. (2013) · European Journal of Immunology · doi:10.1002/eji.201343448 · Cited by 284 · see citing works

Types of dietary fat and breast cancer: A pooled analysis of cohort studies

Smith‐Warner, S. A., Spiegelman, D. L., Adami, H., Beeson, W. L., van den Brandt, P. A., Folsom, A. R., Fraser, G. E., Freudenheim, J. L., Goldbohm, R. A., Graham, S., et al. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010601)92:5 · Cited by 279 · see citing works

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma

Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267 · see citing works

Cytosolic Delivery of Granzyme B by Bacterial Toxins: Evidence that Endosomal Disruption, in Addition to Transmembrane Pore Formation, Is an Important Function of Perforin

Browne, K. A., Blink, E. J., Sutton, V. R., Froelich, C. J., Jans, D. A., & Trapani, J. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.12.8604 · Cited by 208 · see citing works

IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells

Mao, Y., van Hoef, V., Zhang, X., Wennerberg, E., Lorent, J., Witt, K., Masvidal, L., Liang, S., Murray, S. M., Larsson, O. S., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698027 · Cited by 171 · see citing works

hOGG1 polymorphism and loss of heterozygosity (LOH): Significance for lung cancer susceptibility in a caucasian population

Wikman, H., Risch, A., Klimek, F., Schmezer, P., Spiegelhalder, B., Dienemann, H., Kayser, K., Schulz, V., Drings, P., & Bartsch, H. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001215)88:6 · Cited by 161 · see citing works

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma

Navid, F., Willert, J. R., McCarville, M. B., Furman, W. L., Watkins, A., Roberts, W., & Daw, N. C. (2008) · Cancer · doi:10.1002/cncr.23586 · Cited by 153 · see citing works

Involvement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in NK Cell-Mediated and IFN-γ-Dependent Suppression of Subcutaneous Tumor Growth

Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Yamaguchi, N., Yagita∥, H., & Okumura, K. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1896 · Cited by 151 · see citing works

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

Dobrenkov, K., Ostrovnaya, I., Gu, J., Cheung, I. Y., & Cheung, N. V. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26097 · Cited by 149 · see citing works

Prognostic significance of HLA class I expression in osteosarcoma defined by anti‐pan HLA class I monoclonal antibody, EMR8‐5

Tsukahara, T., Kawaguchi, S., Torigoe, T., Asanuma, H., Nakazawa, E., Shimozawa, K., Nabeta, Y., Kimura, S., Kaya, M., Nagoya, S., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00317.x · Cited by 148 · see citing works

Donor–Recipient Combinations of Group A and B KIR Haplotypes and HLA class I Ligand Affect the Outcome of HLA-Matched, Sibling Donor Hematopoietic Cell Transplantation

McQueen, K. L., Dorighi, K. M., Guethlein, L. A., Wong, R. M., Sanjanwala, B. M., & Parham, P. (2007) · Human Immunology · doi:10.1016/j.humimm.2007.01.019 · Cited by 133 · see citing works

Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial

Canter, R. J., Grossenbacher, S. K., Foltz, J. A., Sturgill, I. R., Park, J. S., Luna, J. I., Kent, M. S., Culp, W. T. N., Chen, M., Modiano, J. F., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0305-7 · Cited by 127 · see citing works

Cellular therapy: Adoptive immunotherapy with expanded natural killer cells

Lee, D. A. (2019) · Immunological Reviews · doi:10.1111/imr.12793 · Cited by 123 · see citing works

Natural killer cells: integrating diversity with function

Cheent, K. S., & Khakoo, S. I. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03045.x · Cited by 122 · see citing works

Histone deacetylase inhibitors suppress natural killer cell cytolytic activity

Ogbomo, H., Michaelis, M., Kreuter, J., Doerr, H. W., & Cinatl, J. J. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.02.045 · Cited by 111 · see citing works

The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells

Zhu, S., Denman, C. J., Cobanoglu, Z. S., Kiany, S., Lau, C. C., Gottschalk, S. M., Hughes, D. P. M., Kleinerman, E. S., & Lee, D. A. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1231-0 · Cited by 110 · see citing works

Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells

Márkász, L., Stuber, G., Vanherberghen, B., Flaberg, E., Oláh, É., Carbone, E., Eksborg, S., Klein, E., Skribek, H., & Székely, L. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0358 · Cited by 110 · see citing works

IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas

Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E., Zhou, S. X., Albert, C. M., Moy, F., Sachdev, D., Yee, D., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133152 · Cited by 109 · see citing works

Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma

Pahl, J. H. W., Ruslan, S. E. N., Buddingh, E. P., Santos, S. J., Szuhai, K., Serra, M., Gelderblom, H. A. J., Hogendoorn, P. C. W., Egeler, R. M., Schilham, M. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2277 · Cited by 108 · see citing works

Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy

Liu, Y., Wu, H.-W., Sheard, M. A., Sposto, R., Somanchi, S. S., Cooper, L. J. N., Lee, D. A., & Seeger, R. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1243 · Cited by 105 · see citing works

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G

Kailayangiri, S., Altvater, B., Spurny, C., Jamitzky, S., Schelhaas, S., Jacobs, A. H., Wiek, C., Roellecke, K., Hanenberg, H., Hartmann, W., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1250050 · Cited by 104 · see citing works

Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells

Buddingh, E. P., Schilham, M. W., Ruslan, S. E. N., Berghuis, D., Szuhai, K., Suurmond, J., Taminiau, A. H. M., Gelderblom, H. A. J., Egeler, R. M., Serra, M., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0965-3 · Cited by 95 · see citing works

A Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image Cytometry

Somanchi, S. S., McCulley, K. J., Somanchi, A., Chan, L. L., & Lee, D. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141074 · Cited by 93 · see citing works

PD-1 and PD-L1 expression in bone and soft tissue sarcomas

Torabi, A., Amaya, C. N., Wians, F. H., & Bryan, B. A. (2017) · Pathology · doi:10.1016/j.pathol.2017.05.003 · Cited by 78 · see citing works

Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D–NKG2DL dependent manner

Fernández, L., Valentín, J., Zalacaín, M., Leung, W. H., Patiño‐García, A., & Pérez‐Martínez, A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.042 · Cited by 77 · see citing works

Fas ligand and lytic granule differentially control cytotoxic dynamics of natural killer cell against cancer target

Zhu, Y., Huang, B. Y., & Shi, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9980 · Cited by 73 · see citing works

Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression

Xu, X., Rao, G., Groh, V., Spies, T. A., Gattuso, P., Kaufman, H. L., PLATE, J. M. D., & Prinz, R. A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-194 · Cited by 71 · see citing works

Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma

Poon, V. I., Roth, M. E., Piperdi, S., Geller, D., Gill, J. B., Rudzinski, E. R., Hawkins, D. S., & Gorlick, R. G. (2015) · Clinical Sarcoma Research · doi:10.1186/s13569-014-0020-9 · Cited by 69 · see citing works

A Programmed Switch from IL-15- to IL-2-Dependent Activation in Human NK Cells

Pillet, A.-H., Bugault, F., Thèze, J., Chakrabarti, L. A., & Rose, T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801933 · Cited by 68 · see citing works

Corruption of the Fas Pathway Delays the Pulmonary Clearance of Murine Osteosarcoma Cells, Enhances Their Metastatic Potential, and Reduces the Effect of Aerosol Gemcitabine

Gordon, N. B., Koshkina, N. V., Jia, S.-F., Khanna, C., Mendoza, A., Worth, L. L., & Kleinerman, E. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0313 · Cited by 68 · see citing works

Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines

Aquino‐López, A., Senyukov, V., Vlasic, Z., Kleinerman, E. S., & Lee, D. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00391 · Cited by 65 · see citing works

Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions

Kopp, L. M., Ray, A., Denman, C. J., Senyukov, V., Somanchi, S. S., Zhu, S., & Lee, D. A. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2012.12.012 · Cited by 63 · see citing works

Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1α-dependent manner

Yamada, N., Yamanegi, K., Ohyama, H., Hata, M., Nakasho, K., Futani, H., Okamura, H., & Terada, N. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1630 · Cited by 62 · see citing works

Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report

Berg, S. L., Cairo, M. S., Russell, H. V., Ayello, J., Ingle, A. M., Lau, H. S. H., Chen, N., Adamson, P. C., & Blaney, S. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8387 · Cited by 62 · see citing works

Untitled work

(2001) · PubMed · Cited by 61 · see citing works

TGFβ Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion

Foltz, J. A., Moseman, J. E., Thakkar, A., Chakravarti, N., & Lee, D. A. (2018) · Cancers · doi:10.3390/cancers10110423 · Cited by 61 · see citing works

Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma

Moore, C. E., Eslin, D. E., Levy, A., Roberson, J. R., Giusti, V., & Sutphin, R. M. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22673 · Cited by 60 · see citing works

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers

Wu, L., Parton, A., Lu, L., Adams, M., Schafer, P. H., & Bartlett, J. B. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0919-9 · Cited by 58 · see citing works

Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas

Rapkin, L. B., Qayed, M. D., Brill, P., Martin, M., Clark, D., George, B. A., Olson, T. A., Wasilewski‐Masker, K. J., Alazraki, A. L., & Katzenstein, H. M. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24101 · Cited by 56 · see citing works

CD54/ICAM-1 Is a Costimulator of NK Cell-Mediated Cytotoxicity

Chong, A. S., Boussy, I. A., Jiang, X. L., Lamas, M., & Graf, L. H. (1994) · Cellular Immunology · doi:10.1006/cimm.1994.1208 · Cited by 54 · see citing works

Natural killer cell therapy and aerosol interleukin‐2 for the treatment of osteosarcoma lung metastasis

Guma, S. R., Lee, D. A., Yu, L., Gordon, N. B., Hughes, D. P. M., Stewart, J., Wang, W., & Kleinerman, E. S. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24801 · Cited by 49 · see citing works

Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity

Yamanegi (2010) · Oncology Reports · doi:10.3892/or_00001026 · Cited by 49 · see citing works

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition

Modica, M. D., Sfondrini, L., Regondi, V., Varchetta, S., Oliviero, B., Mariani, G., Bianchi, G., Generali, D., Balsari, A., Triulzi, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6353 · Cited by 47 · see citing works

Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.

Talmadge, J. E., Schneider, M., Collins, M. S., Phillips, H., Herberman, R. B., & Wiltrout, R. H. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.2.1477 · Cited by 44 · see citing works

Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system.

Morisaki, T., Onishi, H., Koya, N., Kiyota, A., Tanaka, H., Umebayashi, M., Ogino, T., Nagamatsu, I., & Katano, M. (2011) · PubMed · Cited by 44 · see citing works

IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis

Honorati, M. C., Neri, S., Cattini, L., & Facchini, A. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02234.x · Cited by 43 · see citing works

Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins

Mirandola, P., Sponzilli, I., Gobbi, G., Marmiroli, S., Rinaldi, L., Binazzi, R., Piccari, G. G., Ramazzotti, G., Gaboardi, G., Cocco, L., et al. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.1.127 · Cited by 43 · see citing works

The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases

Rao‐Bindal, K., Koshkina, N. V., Stewart, J., & Kleinerman, E. S. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313040005 · Cited by 43 · see citing works

Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?

Lee, J. A., Ko, Y., Kim, D. H., Lim, J. S., Kong, C., Cho, W. H., Jeon, D., Lee, S., & Koh, J.-S. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.3.202 · Cited by 41 · see citing works

In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides

Fujii, H., Trudeau, J. D., Teachey, D. T., Fish, J. D., Grupp, S. A., Schultz, K. R., & Reid, G. S. D. (2006) · Blood · doi:10.1182/blood-2006-02-002055 · Cited by 41 · see citing works

Aerosol interleukin‐2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis

Guma, S. R., Lee, D. A., Yu, L., Gordon, N. B., & Kleinerman, E. S. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25019 · Cited by 40 · see citing works

Contrasting effects of the cytotoxic anticancer drug gemcitabine and the EGFR tyrosine kinase inhibitor gefitinib on NK cell-mediated cytotoxicity via regulation of NKG2D ligand in non-small-cell lung cancer cells

Okita, R., Wolf, D., Yasuda, K., Maeda, A., Yukawa, T., Saisho, S., Shimizu, K., Yamaguchi, Y., Oka, M., Nakayama, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139809 · Cited by 39 · see citing works

Interferon-? conjugation to human osteogenic sarcoma monoclonal antibody 791T/36

Pelham, J. M., Gray, J. D., Flannery, G. R., Pimm, M. V., & Baldwin, R. W. (1983) · Cancer Immunology Immunotherapy · doi:10.1007/bf00199167 · Cited by 38 · see citing works

Immunomodulation in a Treatment Program Including Pre- and Post-Operative Interleukin-2 and Chemotherapy for Childhood Osteosarcoma

Luksch, R., Perotti, D., Cefalo, G., Gambacorti-Passerini, C. B., Massimino, M., Spreafico, F., Casanova, M., Ferrari, A., Terenziani, M., Polastri, D., et al. (2003) · Tumori Journal · doi:10.1177/030089160308900306 · Cited by 37 · see citing works

Natural killer cells in malignant hematology: A primer for the non-immunologist

Kannan, G. S., Aquino‐López, A., & Lee, D. A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.08.007 · Cited by 32 · see citing works

Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis.

Kubista, B., Trieb, K., Blahovec, H., Kotz, R. I., & Micksche, M. (2002) · PubMed · Cited by 29 · see citing works

MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts

Rao‐Bindal, K., Zhou, Z., & Kleinerman, E. S. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.101 · Cited by 28 · see citing works

NK cell and macrophages confer prognosis and reflect immune status in osteosarcoma

Yang, X., Zhang, W., & Xu, P. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28167 · Cited by 28 · see citing works

Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death

Yamanegi, K. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1438 · Cited by 27 · see citing works

Interleukin‐12 Induces Efficient Lysis of Natural Killer‐Sensitive and Natural Killer‐Resistant Human Osteosarcoma Cells: the Synergistic Effect of Interleukin‐2

Mariani, E., Meneghetti, Tarozzi, Cattini, & Facchini (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00737.x · Cited by 25 · see citing works

Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients

Pittari, G., Fregni, G., Roguet, L., Garcia, A., Vataire, A.-L., Wittnebel, S., Amsellem, S., Chouaı̈b, S., Bourhis, J.-H., & Caignard, A. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.265 · Cited by 24 · see citing works

KIR receptor‐ligand incompatibility predicts killing of osteosarcoma cell lines by allogeneic NK cells

Delgado, D. C., Webster, D. E., DeSantes, K. B., Durkin, E. T., & Shaaban, A. F. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22665 · Cited by 24 · see citing works

Prevalent expression of MHC class I chain-related molecule A in human osteosarcoma.

Lu, S., Xiao, P., Xue, L., Che, L.-H., Yang, P., Li, Y., & Qiao, H. (2008) · PubMed · Cited by 21 · see citing works

Human osteosarcoma cell susceptibility to natural killer cell lysis depends on CD54 and increases after TNFα incubation

Mariani, E., Tarozzi, A., Meneghetti, A., Cattini, L., & Facchini, A. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00247-0 · Cited by 21 · see citing works

Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells

Liebau, C., Merk, H. R., Schmidt, S., Roesel, C., Karreman, C., Prisack, J. B., Bojar, H., & Baltzer, A. W. A. (2002) · Cytokines Cellular & Molecular Therapy · doi:10.1080/13684730310001977 · Cited by 20 · see citing works

Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity

Pahl, J. H. W., Ruslan, S. E. N., Kwappenberg, K. M. C., Dam, M. M. V. O.-T., van Tol, M. J. D., Lankester, A. C., & Schilham, M. W. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1406-x · Cited by 19 · see citing works

Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients

Buddingh, E. P., Ruslan, S. E. N., Berghuis, D., Gelderblom, H. A. J., Anninga, J., Hogendoorn, P. C. W., Egeler, R. M., Schilham, M. W., & Lankester, A. C. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1232-6 · Cited by 19 · see citing works

Anti-ganglioside GD2 monoclonal antibody synergizes with cisplatin to induce endoplasmic reticulum-associated apoptosis in osteosarcoma cells

Zhu, W., Mao, X., Wang, W., Chen, Y., Li, D., Li, H., & Dou, P. (2018) · Die Pharmazie · doi:10.31083/ph.2018.7836 · Cited by 17 · see citing works

[Evaluation of selected parameters of cellular immunity in children with osteosarcoma at diagnosis].

Markiewicz, K., Zeman, K., Kozar, A., Gołębiowska-Wawrzyniak, M., & Woźniak, W. (2012) · PubMed · Cited by 14 · see citing works

Tiazofurin Induces a Down-Modulation of ICAM-1 Expression on K562 Target Cells Impairing NK Adhesion and Killing

Zamai, L., Zauli, G., Bavelloni, A., Marmiroli, S., Cataldi, A., Weber, G., & Vitale, M. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1147 · Cited by 14 · see citing works

Expression and roles of MICA in human osteosarcoma

Xiao, P., Xue, L., Che, L., Peng, J., Wu, H., Li, Y., & Qiao, H. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.02989.x · Cited by 13 · see citing works

Immunomodulation: NK cells activated by interferon-conjugated monoclonal antibody against human osteosarcoma

Flannery, G. R., Pelham, J. M., Gray, J. D., & Baldwin, R. W. (1984) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(84)90218-9 · Cited by 12 · see citing works

NK binding capacity and lytic activity depend on the expression of ICAM-1 on target bone tumours.

Meneghetti, A., Mariani, E., Santi, S., Riccio, M., Cattini, L., Paoletti, S., & Facchini, A. (1999) · International Journal of Oncology · doi:10.3892/ijo.15.5.909 · Cited by 12 · see citing works

TNF-alpha but not IL-1 and IL-6 modifies the susceptibility of human osteosarcoma cells to NK lysis.

Mariani, E., Tarozzi, A., Meneghetti, A., Cattini, L., & Facchini, A. (1998) · International Journal of Oncology · doi:10.3892/ijo.13.2.349 · Cited by 9 · see citing works

In vitro cytolytic activity of human NK cells against osteosarcoma cell lines.

Tarozzi, A., Mariani, E., & Facchini, A. (1996) · PubMed · Cited by 4 · see citing works

The role of interferon gamma and NK cells in the eradication of pulmonary osteosarcoma metastases by IL-12

Mills, L., Huang, G., & Worth, L. L. (2005) · Cancer Research · Cited by 3 · see citing works

Advancing therapy for osteosarcoma

Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876 · see citing works

Osteosarcoma

Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works

Advancements in Osteosarcoma Therapy: Overcoming Chemotherapy Resistance and Exploring Novel Pharmacological Strategies

Zhra, M., Akhund, S. A., & Mohammad, K. S. (2025) · Pharmaceuticals · doi:10.3390/ph18040520 · Cited by 36 · see citing works

Prospects for NK Cell Therapy of Sarcoma

Lachota, M., Vincenti, M., Winiarska, M., Boye, K., Zagożdżon, R., & Malmberg, K. (2020) · Cancers · doi:10.3390/cancers12123719 · Cited by 26 · see citing works

Development of a Machine Learning-Based Autophagy-Related lncRNA Signature to Improve Prognosis Prediction in Osteosarcoma Patients

Zhang, G., Wu, Z., Li, C., Ren, E., Yuan, W., Deng, Y.-J., & Xie, Q. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.615084 · Cited by 25 · see citing works

Spatial multiplexed immunofluorescence analysis reveals coordinated cellular networks associated with overall survival in metastatic osteosarcoma

Lacinski, R. A., Dziadowicz, S. A., Melemai, V. K., Fitzpatrick, B., Pisquiy, J. J., Heim, T. E., Lohse, I., Schoedel, K. E., Llosa, N. J., Weiss, K. R., et al. (2024) · Bone Research · doi:10.1038/s41413-024-00359-z · Cited by 22 · see citing works

Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma

Kisseberth, W. C., & Lee, D. A. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.672361 · Cited by 20 · see citing works

A cuproptosis-related genes signature associated with prognosis and immune cell infiltration in osteosarcoma

Yang, W., Wu, H., Tong, L., Wang, Y., Guo, Q., Xu, L., Yan, H., Yin, C., & Sun, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1015094 · Cited by 18 · see citing works

Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance

Razmara, A. M., Judge, S. J., Gingrich, A. A., Cruz, S. M., Culp, W. T. N., Kent, M. S., Rebhun, R. B., & Canter, R. J. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.771737 · Cited by 12 · see citing works

Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma

Lu, X., Liu, M., Yang, J., Que, Y., & Zhang, X. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac068 · Cited by 11 · see citing works

A Disulfidptosis-Related Gene Signature Associated with Prognosis and Immune Cell Infiltration in Osteosarcoma

Chen, P., & Shen, J. (2023) · Bioengineering · doi:10.3390/bioengineering10101121 · Cited by 8 · see citing works

Targeting the osteosarcoma immune microenvironment for improved immunotherapy and translational applications

Cai, J., Qiu, S., Sun, B., Ge, J., Yu, Z., & Wang, C. (2025) · Discover Oncology · doi:10.1007/s12672-025-04315-z · Cited by 4 · see citing works

A glycometabolic gene signature associating with immune infiltration and chemosensitivity and predicting the prognosis of patients with osteosarcoma

Wang, F., Yang, K., Pan, R., Xiang, Y., Xiong, Z., Li, P., Li, K., & Sun, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1115759 · Cited by 3 · see citing works

Development and evaluation of an inhalable nanoemulsion system for enhancing NK cell function against osteosarcoma pulmonary metastases

Hwang, S., Bates, P. D., Valkanioti, V., Chang, C. S., Mecozzi, S., & Capitini, C. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1772375 · Cited by 2 · see citing works

Immunotherapy of Osteosarcoma

Sorteberg, A. L., Ek, L., Lilienthal, I., & Herold, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_236-1 · Cited by 2 · see citing works

RNA modification‐related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single‐cell sequencing analysis

Qin, H., Yang, S., Feng, Z., Wu, S. J., Cai, T., Xie, Z., & Hu, H. (2024) · Environmental Toxicology · doi:10.1002/tox.24261 · Cited by 2 · see citing works

NETs-related genes predict prognosis and are correlated with the immune microenvironment in osteosarcoma

Chu, D., Huang, R., Shi, J., Xu, R., & Wei, D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1551074 · Cited by 2 · see citing works

Immunotherapy of Osteosarcoma

Sorteberg, A. L., Ek, L., Lilienthal, I., & Herold, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_236 · Cited by 1 · see citing works

Correlation between systemic immune inflammatory index and prognostic nutritional index and prognosis of osteosarcoma patients and construction of prediction model

Huang, Q., Li, J., Sun, X., & Sun, Z. (2026) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-026-09494-6 · Cited by 1 · see citing works

NET-related genes predict prognosis and are correlated with the immune microenvironment in osteosarcomaPreprint

Chu, D., Huang, R., Shi, J., Xu, R., & Wei, D. (2024) · Research Square · doi:10.21203/rs.3.rs-5332874/v1

Amino acid metabolism-related genes signature correlates with immune infiltration and predicts clinic prognosis in osteosarcoma

Xi, D., Teng, Y., Wang, S., Zhang, M., Liu, G., Han, B., Zhang, Y. T., Tian, X., Cheng, C., Wang, S., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-15746-4

Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours

Weisnicht, A. M., Szewc, F., Cho, M. M., Cheng, H.-Y. H., Ganesh, S., Mahoney, L., Fox, K. C., Smith, P. R., Olsen, M., Richards, R. M., et al. (2026) · Veterinary and Comparative Oncology · doi:10.1111/vco.70091

Natural Killer Cells for Osteosarcoma

Tarek, N., & Lee, D. A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_19 · Cited by 32 · see citing works

Promoting NK cell trafficking to improve therapeutic effect of NK cell therapy on osteosarcoma

Yang, Y., Gordon, N. B., Kleinerman, E. S., & Huang, G. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p24 · Cited by 9 · see citing works

Reprogramming CXCL10-mediated NK cell trafficking to enhance immunotherapy in osteosarcoma

Jayne, W. P., Freilich, M. E., Solanki, R., & Challagundla, K. B. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201169

Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D–NKG2DL dependent manner

Fernández, L., Valentín, J., Zalacaín, M., Leung, W. H., Patiño‐García, A., & Pérez‐Martínez, A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.042 · Cited by 77 · see citing works

Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma

Kisseberth, W. C., & Lee, D. A. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.672361 · Cited by 20 · see citing works